Although the country is in the midst of the darkest period of the coronavirus pandemic, with emergency authorization of a COVID-19 vaccine imminent and distribution of initial doses expected to start this month, the beginning of the end is starting to come into focus. Today a panel of experts that advises the Food and Drug Administration (FDA) on drug approval is meeting to review data on the vaccine candidates from Pfizer-BioNTech. Emergency use authorization (EUA) for the vaccine could come shortly thereafter. The advisory committee will review data on the Moderna vaccine on Dec 17.

 

Ali Siraj

Read more CIDRAP…